Anti-Cancer

Dabrafenib (RAFINLAR) 30 Tablet

$2,830.00

Reatment with Dabrafenib Rafinlar HNC 50/75 MG Tablet should be initiated and monitored by a qualified oncologist or healthcare provider experienced in the management of melanoma and NSCLC. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.

Strength	Choose an option50mg75mg
	Clear

Quantity

Dabrafenib (RAFINLAR) 30 Tablet quantity

Add to cart

Sku:

N/A

Tag:

Dabrafenib RAFINLAR

Description

Dabrafenib Rafinlar HNC 50/75 MG Tablet is a targeted therapy medication used in the treatment of certain types of metastatic melanoma and non-small cell lung cancer (NSCLC) with specific genetic mutations. It contains dabrafenib as its active ingredient, a potent inhibitor of the BRAF protein kinase, which plays a key role in the regulation of cell growth and proliferation.

Key Features:

• BRAF Kinase Inhibitor: Dabrafenib exerts its therapeutic effects by selectively inhibiting the activity of BRAF kinases, particularly those with the V600 mutation, which is commonly found in melanoma and NSCLC. By blocking BRAF signaling pathways, dabrafenib effectively suppresses tumor growth and progression in patients with these specific genetic mutations.
• Treatment of Metastatic Melanoma: Dabrafenib Rafinlar HNC 50/75 MG Tablet is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test. It offers a targeted treatment option for patients with this aggressive form of skin cancer.
• Treatment of NSCLC: Dabrafenib, in combination with trametinib, is also indicated for the treatment of patients with metastatic NSCLC with BRAF V600E mutation, as detected by an FDA-approved test. This combination therapy provides an effective treatment option for NSCLC patients with this specific genetic alteration.
• Oral Administration: Dabrafenib Rafinlar HNC 50/75 MG Tablet is administered orally, typically twice daily, with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Efficacy: Clinical trials have demonstrated the efficacy of dabrafenib in prolonging progression-free survival and overall survival in patients with metastatic melanoma and NSCLC harboring BRAF V600E mutation. It has shown superiority over standard chemotherapy regimens, offering new hope for patients with these aggressive cancers.
• Safety Profile: Dabrafenib has a manageable safety profile, with common side effects including fever, fatigue, rash, nausea, and headache. Patients should be closely monitored for adverse reactions, and dose adjustments may be necessary to manage side effects effectively.
• Patient Education: Patients prescribed Dabrafenib Rafinlar HNC 50/75 MG Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
• Consultation with Healthcare Provider: Treatment with Dabrafenib Rafinlar HNC 50/75 MG Tablet should be initiated and monitored by a qualified oncologist or healthcare provider experienced in the management of melanoma and NSCLC. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Dabrafenib Rafinlar HNC 50/75 MG Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to targeted therapy medications is crucial to improving patient outcomes and quality of life for those with specific genetic mutations driving cancer progression.

Additional information